Low Recruitment in a Double-Blind, Placebo-Controlled Trial of Ocrelizumab for Autoimmune Encephalitis: A Case Series and Review of Lessons Learned.
Kyle M BlackburnDavid A DenneySteven C HopkinsSteven A VerninoPublished in: Neurology and therapy (2022)
ClinicalTrials.gov identifier: NCT03835728.